Wu Li, Xu Qian, Zhou Mengxi, Chen Yajing, Jiang Chunyan, Jiang Yuhan, Lin Yin, He Qing, Zhao Lei, Dong Yourong, Liu Jianren, Chen Wei
Department of Neurology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Front Neurosci. 2022 May 17;16:865139. doi: 10.3389/fnins.2022.865139. eCollection 2022.
Small molecule RNAs (miRNAs) could induce downregulation of α-synuclein (SNCA) expression by binding the 3' untranslated region of SNCA, thus playing an important role in the pathogenesis of Parkinson's disease (PD). Recent studies suggest that SNCA-related miRNAs in saliva are promising PD biomarkers. Research on those miRNAs in plasma is rare in patients with PD.
To detect the plasma expression levels of three SNCA related miRNAs (miR-7, miR-153, and miR-223) in PD, and to explore their diagnostic value and associations with clinical phenotype.
MiR-7, miR-153, and miR-223 levels were detected in the plasma of 75 PD patients and 73 normal controls (NCs) real-time quantitative polymerase chain reaction. The receiver operating characteristic (ROC) curves were delineated to evaluate their diagnostic value in PD. In addition, their associations with demographic, key motor, and non-motor symptoms were explored by serial scales.
The expression levels of plasma miR-153 and miR-223 were significantly decreased in patients with PD relative to NCs. The area under the ROC curve separating PD from NCs was 63.1% for miR-153 and 86.2% for miR-223, respectively. The plasma miR-153 level in PD was lower than that in treated patients ( = 0.006), its level increased gradually with disease duration ( = 0.358, = 0.002) and Unified Parkinson's Disease Rating Scale Part III score ( = 0.264, = 0.022). Plasma miR-223 level was decreased in patients with clinical possible rapid eye movement sleep behavior disorder (cpRBD) compared with those without cpRBD ( < 0.001), and its level was negatively associated with RBDSQ score ( = -0.334, = 0.003). Multiple linear regression analysis revealed that disease duration ( = 0.049) was the independently associated factor of miR-153 level; whereas, RBDSQ ( = 0.009) was related to miR-223 level in PD.
Plasma miR-153 and miR-223 levels could be potential biomarkers of PD.
小分子RNA（miRNA）可通过结合α-突触核蛋白（SNCA）的3'非翻译区诱导SNCA表达下调，从而在帕金森病（PD）的发病机制中发挥重要作用。最近的研究表明，唾液中与SNCA相关的miRNA有望成为PD生物标志物。在PD患者中，关于血浆中这些miRNA的研究较少。
检测PD患者血浆中三种与SNCA相关的miRNA（miR-7、miR-153和miR-223）的表达水平，探讨其诊断价值以及与临床表型的关系。
采用实时定量聚合酶链反应检测75例PD患者和73例正常对照（NC）血浆中miR-7、miR-153和miR-223的水平。绘制受试者工作特征（ROC）曲线以评估其对PD的诊断价值。此外，通过系列量表探讨它们与人口统计学、主要运动和非运动症状的关系。
与NC相比，PD患者血浆miR-153和miR-223的表达水平显著降低。区分PD与NC的ROC曲线下面积，miR-153为63.1%，miR-223为86.2%。PD患者血浆miR-153水平低于接受治疗的患者（P = 0.006），其水平随病程逐渐升高（r = 0.358，P = 0.002）和统一帕金森病评定量表第三部分评分升高（r = 0.264，P = 0.022）。与无临床可能快速眼动睡眠行为障碍（cpRBD）的患者相比，有cpRBD的PD患者血浆miR-223水平降低（P < 0.001），且其水平与RBDSQ评分呈负相关（r = -0.334，P = 0.003）。多元线性回归分析显示，病程（β = 0.049）是miR-153水平的独立相关因素；而RBDSQ（β = 0.009）与PD患者miR-223水平相关。
血浆miR-153和miR-223水平可能是PD的潜在生物标志物。
